Provided by Tiger Fintech (Singapore) Pte. Ltd.

RenovoRx Inc

0.9403
+0.04695.25%
Volume:110.74K
Turnover:103.50K
Market Cap:34.46M
PE:-2.60
High:0.9500
Open:0.9000
Low:0.8820
Close:0.8934
52wk High:1.69
52wk Low:0.7500
Shares:36.65M
Float Shares:30.09M
Volume Ratio:0.24
T/O Rate:0.37%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3612
EPS(LYR):-0.3958
ROE:-107.11%
ROA:-54.82%
PB:3.24
PE(LYR):-2.38

Loading ...

Buy Rating Affirmed for RenovoRx Amid Promising Phase 3 Study Progress and Potential Stock Catalyst

TIPRANKS
·
Aug 20

RenovoRx Revenue Jumps 28 Percent in Q2

Motley Fool
·
Aug 15

RenovoRx Reports Strong Q2 2025 Revenue Growth

TIPRANKS
·
Aug 15

RenovoRx Q2 EPS $(0.08) Beats $(0.09) Estimate, Sales $422.00K Beat $329.67K Estimate

Benzinga
·
Aug 15

RenovoRx Inc. Reports Q2 2025 Revenue of Over $400,000, Marking Significant Commercial Growth for RenovoCath Device

Reuters
·
Aug 15

BRIEF-RenovoRx Q2 Net Income USD -2.895 Million

Reuters
·
Aug 15

RenovoRx Inc. Expands Tumor Treatment Innovation with New Patent for TAMP Therapy Platform

Reuters
·
Aug 15

RenovoRx Q2 Basic EPS USD -0.08

THOMSON REUTERS
·
Aug 15

RenovoRx Inc expected to post a loss of 8 cents a share - Earnings Preview

Reuters
·
Aug 13

Meet RenovoRx: Fly exclusive interview with CEO Shaun Bagai

TIPRANKS
·
Aug 08

RenovoRx CEO sees disconnect with Wall Street, believes shares undervalued

TIPRANKS
·
Aug 08

RenovoRx not far from driving revenue to cover cash burn, CEO says

TIPRANKS
·
Aug 08

RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire

GlobeNewswire
·
Aug 06

RenovoRx Inc. Launches PanTheR Post-Marketing Registry Study to Evaluate RenovoCath's Effectiveness in Treating Solid Tumors

Reuters
·
Jul 28

RenovoRx Inc. Announces Second Quarter 2025 Financial Results Release

Reuters
·
Jul 14

RenovoRx Inc. Conducted Annual Stockholders Meeting

Reuters
·
Jun 26

Ramtin Agah, Chief Medical Officer, Reports Acquisition of RenovoRx Inc. Common Shares

Reuters
·
Jun 09

Ascendiant Remains a Buy on RenovoRx (RNXT)

TIPRANKS
·
Jun 05

RenovoRx Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
Jun 05

RenovoRx (RNXT) Receives a Buy from Alliance Global Partners

TIPRANKS
·
May 19